Features Partner Sites Information LinkXpress
Sign In
Advertise with Us


22 May 2018 - 25 May 2018
26 May 2018 - 27 May 2018
04 Jun 2018 - 07 Jun 2018

Levels of SIRT6 Linked to Neurodegenerative Disease

By BiotechDaily International staff writers
Posted on 30 May 2017
Print article
Image: The structure of the human SIRT6 protein (Photo courtesy of the Protein Data Bank).
Image: The structure of the human SIRT6 protein (Photo courtesy of the Protein Data Bank).
Low levels of the protein SIRT6 (Sirtuin-6) have been linked to aging-like changes in cells including the hyperphosphorylation of Tau, a critical marker in several neurodegenerative diseases such as Alzheimer's.

SIRT6 is a chromatin-associated protein that is required for normal base excision repair of DNA damage in mammalian cells. Deficiency of SIRT6 in mice leads to abnormalities that overlap with aging-associated degenerative processes. SIRT6 also promotes the repair of DNA double-strand breaks by the process of non-homologous end joining.

Investigators at Ben-Gurion University of the Negev worked with a line of mice that had been genetically engineered to lack the gene for SIRT6 specifically in brain tissue. They reported in the March 28, 2017, issue of the journal Cell Reports that while knockout mice completely lacking SIRT6 exhibited an accelerated aging phenotype and died prematurely, brain-specific SIRT6-deficient mice survived but presented behavioral defects with major learning impairments by four months of age. The brains of these mice showed increased signs of DNA damage, cell death, and hyperphosphorylated Tau.

At the molecular level SIRT6 was found to regulate Tau protein stability and phosphorylation through increased activation of the kinase enzyme glycogen synthase kinase 3 alpha/beta (GSK3alpha/beta).

The investigators also found that SIRT6 was almost completely absent in Alzheimer's disease patients, a finding that suggested to them that SIRT6 was critical for maintaining genomic stability in the brain and that its loss led to toxic Tau stability and phosphorylation.

Senior author Dr. Deborah Toiber, a molecular biologist at Ben-Gurion University of the Negev, said, "If a decrease in SIRT6 and lack of DNA repair is the beginning of the chain that ends in neurodegenerative diseases in seniors, then we should be focusing our research on how to maintain production of SIRT6 and avoid the DNA damage that leads to these diseases."

Print article



view channel

Collaborative Agreement to Aid in Setting Guidelines for Evaluating Potential Ebola Therapy

Cooperation between an Israeli biopharmaceutical company and medical branches of the US government is designed to set ground rules for continued evaluation of an experimental therapy for Ebola virus disease. RedHill Biopharma Ltd. (Tel Aviv, Israel), a biopharmaceutical company primarily focused on development and c... Read more
Copyright © 2000-2018 Globetech Media. All rights reserved.